Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Fixed-duration epcoritamab plus R2drives favorable outcomes in relapsed or refractory follicular lymphoma
Published in: Blood
Access to document
10.1182/blood.2025029909
document
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE NHL-2 (phase 1b/2). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years, and R2for up to 12 cycles (28 days per cycle). The primary end point was overall response rate (ORR) per investigator assessment (Lugano criteria). As of 21 September 2024, 108 patients received ≥1 epcoritamab dose in expansion...
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella J. Lugtenburg, Pau Abrisqueta, Kim M. Linton, Gauri Sunkersett, Daniela Hoehn, Ali Rana, Aqeel Abbas, Jennifer Marek, Yi Hao, Andrew J. Steele, Christopher MorehouseMartin Hutchings, David Belada
MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis
Published in: Haematologica
Access to document
10.3324/haematol.2025.287485
document
Fleur A De Groot, Floriske G Stedema, Esther J Kret, Lorraine M De Haan, Patty M Jansen, Stefan Böhringer, Arjan Diepstra, Marjolein W M Van der Poel, Myrurgia Abdul Hamid, Liane C J Te Boome, Valeska Terpstra, Mirian Brink, Hendrik Veelken, Ruben A L De Groen, Tim J A Dekker, Marcel Nijland, Joost S P Vermaat
Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma
Published in: European Journal of Cancer
Access to document
10.1016/j.ejca.2025.115776
document
BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL. METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function...
Diana Al-Sarayfi, Johanna A A Bult, Ruben A L de Groen, Fleur A de Groot, Joost S P Vermaat, Djamilla Issa, Arjan Diepstra, Gerwin Huls, Mar Bellido, Wouter Plattel, Mirian Brink, Marcel Nijland
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025015837
document
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2024015226
document
The risk of relapse among high-risk diffuse large B-cell lymphoma (DLBCL) patients in complete metabolic remission (CMR) following R-CHOP therapy is 20-25%. Here, we evaluated whether consolidation with the PDL-1 checkpoint inhibitor atezolizumab could reduce the relapse risk. In this phase II, open-label trial (NCT03463057) DLBCL patients with an international prognostic index (IPI) score of ≥ 3 and CMR after R-CHOP received 1200mg atezolizumab every 3 weeks for 18 cycles. The primary endpoint was disease-free survival (DFS) at 2 years with the aim of improving it to 89%...
Marcel Nijland, Djamila E Issa, Johanna A A Bult, Dries Deeren, Gerjo A Velders, Marten R Nijziel, Yorick Sandberg, Vibeke Kj Vergote, Margriet Oosterveld, Rob Fijnheer, Rolf Brouwer, Rinske Boersma, Kalung Wu, Laurens Nieuwenhuizen, Joost Sp Vermaat, Roel J W van Kampen, Wim E Terpstra, Sylvia Snauwaert, Marjolein Wm van der Poel, Eva de JonghMarc Durian, Leonie Strobbe, Aart Beeker, Alain Pa Gadisseur, Roos Van Rijn, Otto J Visser, Jeanette Doorduijn, Tjeerd J F Snijders, Matthijs H Silbermann, Daphne de Jong, Martine E D Chamuleau, Rogier Mous, Mathilde Jalving, Heleen Visser-Wisselaar, Sonja Jansen van den Bergh, Gerben Jc Zwezerijnen, Edwin Bremer, Mirian Brink, Arjan Diepstra, Dana A Chitu, Harry R Koene, Josée M Zijlstra